Project Twenty21 changing minds and lives through medical cannabis research
The largest medical cannabis registry in Europe, Project Twenty21, was launched in November 2019 by drug reform campaigning body, Drug Science to enrol 20,000 patients suffering from a variety of conditions by the end of 2021.
Drug Science’s stated goal is to create Europe’s largest single body of evidence supporting the efficacy of medical cannabis to improve patient access to treatment as, despite it being legal in the UK to prescribe medical cannabis on the NHS, few doctors are prescribing it.
To be enrolled in Project Twenty21, patients must have been diagnosed with one or more of the following medical conditions where at least two other licensed medications have failed in the past:
Post Traumatic Stress Disorder (PTSD)
Substance use disorder (as harm reduction strategy)
Patients enrolled in the registry will have access to a number of medicinal cannabis products at a subsidised cost for the duration of the scheme, including THC-only medications, CBD-only medications, and a combination of the two cannabinoids. Several licensed medical cannabis suppliers have announced that they will be providing products for the project.
Patients access Project Twenty21 through a network of private clinics; currently, just two are listed on Drug Science’s clinic directory but more are likely to follow now the project is fully live (as of 4th August 2020).
Clinics will set their own pricing for the initial and follow-up consultations, with costs covered by the patient but, as more clinics come on board, competition will likely push consultation costs down.
“I feel like me again”
Video testimonials from Project Twenty21 patients are already providing powerful testimony to the value of medical cannabis changing lives for the better, with moves away from prescription drugs and pain reduction described as “remarkable” and “life-changing”.
It’s hoped that the results of the two-year-long project will provide hard evidence of the effectiveness and tolerability of medical cannabis that will aid the process of improving patient access to medical cannabis products in the near future, including NHS funding for medicinal cannabis treatment.
To sign up to participate as a Project Twenty21 patient, click here to submit your details.
Interestingly, the UK’s NHS has launched its ‘Patient Registry for Cannabis-Based Products’ this month which Businesscann described as “a significant move for medical cannabis in the country” but, with an estimated 250 patients a month said to be prescribed cannabis medicines through the NHS compared to over 2,500 in the UK’s private sector, it will be of limited value in terms of quality and volume of data. Perhaps viewed in conjunction with Project Twenty21, we will get some real insights into the potential of medical cannabis in treating a wide range of conditions.